Darolutamide Plus Docetaxel/ADT Does Not Increase Hospitalization in mHSPC

Prostate Cancer - stock.adobe.com

The addition of darolutamide (Nubeqa) to docetaxel and androgen deprivation therapy (ADT) was associated with a numerically lower rate of hospitalization compared with placebo during and post treatment with docetaxel in patients with metastatic hormone-sensitive prostate cancer (mHSPC), according to data presented in a poster at the 2024 Genitourinary Cancers Symposium.

Findings from the study also demonstrated that a lower rate of hospitalization was observed after treatment with docetaxel as compared with during docetaxel treatment.

“Treatment with docetaxel may be linked to an increased number of hospitalizations (approximately 2.4 times greater hospitalization rate),” the researchers wrote in the poster. “However, for those hospitalized during treatment with docetaxel, their [length of stay] is shown to be similar in length to those who are hospitalized post-docetaxel use.”

The first 4 months of treatment, during which patients received docetaxel, were associated with increased hospitalization for any cause and for adverse events. Treatment with darolutamide was linked with a numerical reduction in hospitalization rates per year for any reason during docetaxel administration (0.75 days; 95% CI, 0.61-0.88) vs placebo (0.91 days; 95% CI, 0.75-1.07). This was also observed after docetaxel (0.31 days; 95% CI, 0.26-0.37) compared with placebo (0.38 days; 95% CI, 0.31-0.45). Researchers observed a similar trend for adverse event-related hospitalizations.

Regression models estimated that the all-cause hospitalization rate was 2.39-times (95% CI, 2.11-2.70) greater within the first 4 months of treatment compared with after treatment. These models resulted in similar results for adverse event-related hospitalizations (rate ratio = 1.89; 95% CI, 1.63-2.19).

Compared with placebo, darolutamide was associated with a marginally longer length of stay per hospitalization (+1.90 days). Results were similar when assessing the length of stay related to adverse events (+1.67 days).

“Our analyses indicate [length of stay] was not found to vary during and post-treatment with docetaxel in ARASENS, which suggests that if the increased hospitalization rate during docetaxel treatment was attributed to docetaxel use, docetaxel does not lead to more severe hospitalizations requiring a longer [length of stay],” the researchers wrote in the poster.

Researchers used data from the ARASENS trial (NCT02799602) to compare rates of hospitalizations and length of hospital stay per patient either for any reason or related to adverse events during or after treatment with docetaxel. The objective of the ARASENS trial was to assess the addition of darolutamide to docetaxel and androgen deprivation therapy (ADT) for patients with metastatic hormone-sensitive prostate cancer. This particular study assessed data from 651 patients randomly assigned to darolutamide, docetaxel, and ADT and 654 patients assigned to placebo, docetaxel, and ADT.

In this study, researchers used mixed effects negative binomial regression to estimate length of stay and time-varying rate of hospitalization by patient. Researchers considered listings to be duplicates if patients’ records had the same start date, and they condensed them into one visit with the latest end date. Records would be combined into one visit if patients had multiple records within overlapping time periods. 

Researchers considered a constant hospitalization rate assumption inappropriate since docetaxel is administered to patients for 6 cycles, which would take approximately 4.14 months, according to the poster. Patients who were hospitalized within and after the first 4 months of treatment were grouped together. In addition, length of stay was assumed to be time invariant.

Reference

Morgans AK, Boegemann M, Paracha N, et al. Rate of hospitalization and length of hospital stay during and post docetaxel for darolutamide in metastatic hormone-sensitive prostate cancer using ARASENS. J Clin Oncol. 2024;42(suppl 4):228. doi:10.1200/JCO.2024.42.4_suppl.228